Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | BIIB Biogen | ABT Abbott Laboratories |
|---|---|---|
| Price | $215.50 -1.6% | $102.61 +0.4% |
| StockIQ Score | 54C- Moderate Risk: Medium | 51C- Moderate Risk: Medium |
| Technical | 56C | 19F |
| Fundamental | 61C+ | 72B |
| Growth | 34F | 45D+ |
| Fair Value | 38F | 38F |
| News | 98A+ | 100A+ |
| Quality | 47D+ | 63C+ |
| Risk | 54C- | 54C- |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Biogen (BIIB) outperforms Abbott (ABT) in technical strength, scoring 85 versus 50, making it far more stable and potentially better for short-term trading. However, Abbott leads in fundamentals with a 72 score compared to Biogen’s 61, suggesting stronger long-term financial health. Both share equal valuation scores of 38, but Biogen’s higher growth score (34 vs. 45) is misleading—Abbott actually ranks better in growth.